Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Trevena, Inc.
Trevena, Inc. News
Mar 26, 2025 - globenewswire.com
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market
Dec 10, 2024 - zacks.com
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevena, Inc. Quantitative Score
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Trevena, Inc. Financials
Table Compare
Compare TRVN metrics with: | |||
|---|---|---|---|
Earnings & Growth | TRVN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | TRVN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | TRVN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | TRVN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Trevena, Inc. Income
Trevena, Inc. Balance Sheet
Trevena, Inc. Cash Flow
Trevena, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Trevena, Inc. Executives
| Name | Role |
|---|---|
| Ms. Carrie L. Bourdow | President, Chief Executive Officer & Chairman |
| Dr. Mark A. Demitrack M.D. | Senior Vice President & Chief Medical Officer |
| Mr. Barry Shin J.D., M.B.A. | Chief Operating Officer |
| Mr. Robert T. Yoder | Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Carrie L. Bourdow | President, Chief Executive Officer & Chairman | Female | 1963 | 1.08M |
| Dr. Mark A. Demitrack M.D. | Senior Vice President & Chief Medical Officer | 1958 | 741.35K | |
| Mr. Barry Shin J.D., M.B.A. | Chief Operating Officer | Male | 1972 | 722.79K |
| Mr. Robert T. Yoder | Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer | Male | 1966 | 490.64K |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | -- |
Trevena, Inc. Insider Trades
| Date | 26 Nov |
| Name | Sutton Katrine |
| Role | VP, Finance |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 26 Nov |
| Name | Sutton Katrine |
| Role | VP, Finance |
| Transaction | Disposed |
| Type | |
| Shares | 76 |
| Date | 8 Oct |
| Name | Demitrack Mark |
| Role | Acting CMO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 20 |
| Date | 8 Oct |
| Name | Demitrack Mark |
| Role | Acting CMO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 45 |
| Date | 8 Oct |
| Name | Demitrack Mark |
| Role | Acting CMO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 144 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 26 Nov | Sutton Katrine | VP, Finance | Disposed | 0 | |
| 26 Nov | Sutton Katrine | VP, Finance | Disposed | 76 | |
| 8 Oct | Demitrack Mark | Acting CMO | Disposed | F-InKind | 20 |
| 8 Oct | Demitrack Mark | Acting CMO | Disposed | F-InKind | 45 |
| 8 Oct | Demitrack Mark | Acting CMO | Disposed | F-InKind | 144 |